Mehmet Ali Nahit Sendur, MD, on calderasib (MK-1084), alone or in combination, in KRAS G12C–mutant metastatic NSCLC. #ESMO26 Watch now: bit.ly/4zVTPBB

Byoung Chul Cho, MD, PhD (@cbcbc1971), on first data from the phase 2 ROSETTA Lung-107 trial of pumitamig (PD-L1 × VEGF-A bispecific) + docetaxel after chemoimmunotherapy in NSCLC. #ESMO26 Watch now: bit.ly/4dWpn1z

Chantal Decroisette, MD, on the phase 3 PERSEE trial: first-line pembrolizumab with or without platinum-based chemotherapy in advanced NSCLC with PD-L1 ≥50%. #ESMO26 Watch now: bit.ly/4ig8bFH

Daniel Khalaf, MD, on patient-reported quality of life with docetaxel vs. lutetium-177-PSMA-617 in mCRPC from the CCTG PR21 trial. #ESMO26 Watch now: bit.ly/4zRF5n2

Chantal Decroisette, MD, on the phase 3 PERSEE trial: first-line pembrolizumab with or without platinum-based chemotherapy in advanced NSCLC with PD-L1 ≥50%. #ESMO26 Watch now: bit.ly/4ig8bFH

Sarah Howlett, MD, on using a transcriptome classifier to stratify risk and guide ARPI intensification in clinically very high-risk prostate cancer. #ESMO26 Watch now: bit.ly/4igzrUy

Daniel Heng, MD, MPH, FRCPC (@DrDanielHeng), on the final analysis of the phase 3 LITESPARK-011 study: belzutifan + lenvatinib vs. cabozantinib in advanced RCC after anti–PD-(L)1 therapy. #ESMO26 Watch now: bit.ly/4dX3WNQ

Daniel Heng, MD, MPH, FRCPC (@DrDanielHeng), on the final analysis of the phase 3 LITESPARK-011 study: belzutifan + lenvatinib vs. cabozantinib in advanced RCC after anti–PD-(L)1 therapy. #ESMO26 Watch now: bit.ly/4dX3WNQ

HERIZON-GEA-01 at #ESMO26: zanidatamab + chemo improved OS vs. trastuzumab + chemo in HER2+ gastroesophageal cancer (HR 0.76); the tislelizumab triplet kept its OS benefit (HR 0.65). Kohei Shitara, MD (@KoheiShitara), explains. Watch now: bit.ly/4i86pYg

Henning Wege, MD, on the ACTICCA-1 trial: adjuvant gemcitabine + cisplatin vs. standard of care after curative resection of cholangiocarcinoma and gallbladder cancer. #ESMO26 Watch now: bit.ly/4zb2Syz

Zev Wainberg, MD, on additional subgroup analyses from the phase 3 RASolute 302 study of daraxonrasib vs. chemotherapy in previously treated metastatic pancreatic cancer. #ESMO26 Watch now: bit.ly/4yN3nOd

Mark Hull, PhD, FRCP, on the phase 3 EMT2 trial of omega-3 EPA vs. placebo after resection of colorectal cancer liver metastases. #ESMO26 Watch now: bit.ly/4BwGaTc

Jaafar Bennouna, MD, PhD (@BennounaJaafar), on the phase 3 IROCAS trial: adjuvant treatment intensification with mFOLFIRINOX vs. mFOLFOX6 in high-risk stage III colon cancer. #ESMO26 Watch now: bit.ly/4zb2MqH

Pietro De Placido, MD, PhD (@PietroDePlacido), on the final analysis of the GIM3 FATA trial comparing treatment schedules and three aromatase inhibitors in postmenopausal HR+ early breast cancer. #ESMO26 Watch now: bit.ly/4yFMoNK

Young-Joon Kang, MD, PhD, on the randomized AIUR trial: compression therapy with normal-sized surgical gloves to prevent paclitaxel-induced peripheral neuropathy in breast cancer. #ESMO26 Watch now: bit.ly/48e6aVE

Kevin Kalinsky, MD, MS, FASCO (@KalinskyKevin), on overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant in HR+/HER2− advanced breast cancer after a CDK4/6 inhibitor. #ESMO26 Watch now: bit.ly/3VUx1U6

Darren Feldman, MD (@DrDarrenFeldman), on ixotatug vedotin (TORL-1-23), a Claudin 6–targeted ADC, as monotherapy in germ cell tumours. #ESMO26 Watch now: bit.ly/3U0hG3M

Alfonso Gomez de Liano Lista, MD, on KEYNOTE-B15 quality of life: no difference between arms in MIBC; scores recovered after cystectomy in both arms, except sexual function. #ESMO26 Watch now: bit.ly/4ieoXGx

Manish Shah, MD, on the phase 3 KEYNOTE-975 study: pembrolizumab or placebo plus definitive chemoradiotherapy in esophageal and GEJ cancer. #ESMO26 Watch now: bit.ly/4Bnhlsu

Nilofer Azad, MD, FASCO, on COMPANION-002: paclitaxel ± tovecimig (anti-VEGF/DLL4 bispecific) in previously treated advanced biliary tract cancer. #ESMO26 Watch now: bit.ly/4BqfVO2